Loading...
Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens
CD38 is expressed in several types of non-Hodgkin lymphoma (NHL) and constitutes a promising target for antibody-based therapy. Daratumumab (Darzalex) is a first-in-class anti-CD38 antibody approved for the treatment of relapsed/refractory (R/R) multiple myeloma (MM). It has also demonstrated clinic...
Na minha lista:
| Udgivet i: | Haematologica |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Ferrata Storti Foundation
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7109732/ https://ncbi.nlm.nih.gov/pubmed/31296574 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2018.211904 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|